Leiden, the Netherlands – 11 March 2020
Pharming Group N.V. (Euronext Amsterdam: PHARM) today announced that its Chief Financial Officer, Robin Wright, has decided (for family reasons) not to put himself up for re-election as a member of the Board of Management and thus as Chief Financial Officer at the upcoming General Meeting of Shareholders on 20 May 2020 and that, as result of this decision, his term with the Company will end as at that date.
Paul Sekhri, Chairman of the Board of Supervisory Directors, said:
“On behalf of the company, I want to thank Robin for his many contributions to Pharming. Over the past five years, Robin has had an important role in the transformation of our Company to the strong, profitable stand-alone entity that we have become. We thank Robin for his dedication and hard work and wish him well in his future endeavors.”
Sijmen de Vries, Chief Executive of Pharming, said
“Robin’s skills, hard work and dedication played a vital part in getting the deals done that have fundamentally changed Pharming, helping to turning a small Dutch company into an international integrated commercial biopharma company with a strong pipeline and a strong financial base. We would like to thank him for all this and wish him all the best for the future.”
Robin Wright, Chief Financial Officer, commented:
“I have thoroughly enjoyed my five years at Pharming and I look back proudly on what we have achieved. It has been a privilege to be part of the team that has delivered the transformation of Pharming into a successful and profitable international enterprise, with great potential to grow further. I wish the company great success in all its ventures.”
The process of finding a new Chief Financial Officer has been initiated.
About Pharming Group N.V.
Pharming is a specialty pharmaceutical company developing innovative products for the safe, effective treatment of rare diseases and unmet medical needs. Pharming’s lead product, RUCONEST® (conestat alfa) is a recombinant human C1 esterase inhibitor approved for the treatment of acute Hereditary Angioedema (“HAE”) attacks in patients in Europe, the US, Israel and South Korea. The product is available on a named-patient basis in other territories where it has not yet obtained marketing authorisation.
RUCONEST® is commercialised by Pharming in the USA and in Europe, and the Company holds all other commercialisation rights in other countries not specified below. In some of these other countries distribution is made in association with the HAEi Global Access Program (GAP). RUCONEST® is distributed in Argentina, Colombia, Costa Rica, the Dominican Republic, Panama, and Venezuela by Cytobioteck, in South Korea by HyupJin Corporation and in Israel by Kamada.
RUCONEST® is also being evaluated for various additional indications. Pharming’s technology platform includes a unique, GMP-compliant, validated process for the production of pure recombinant human proteins that has proven capable of producing industrial quantities of high quality recombinant human proteins in a more economical and less immunogenetic way compared with current cell-line based methods.
Leads for enzyme replacement therapy (“ERT”) for Pompe and Fabry’s diseases are also being produced and optimised respectively at present.
Pharming has recently in-licensed leniolisib from Novartis, a small molecule and selective PI3K? inhibitor, which is in a registrational study for activated PI3K-delta syndrome (APDS), a rare form of Primary Immunodeficiency.
Pharming has a long term partnership with the China State Institute of Pharmaceutical Industry (“CSIPI”), a Sinopharm company, for joint global development of new products, starting with recombinant human Factor VIII for the treatment of Haemophilia A. Preclinical development and manufacturing will take place to global standards at CSIPI and its affiliates and are funded by CSIPI. Clinical development will be shared between the partners with each partner taking the costs for their territories under the partnership.
